US 12,102,616 B2
Psilocin mucate
Yousry Sayed, Wilmington, NC (US); Frederick Sancilio, Stuart, FL (US); Philip J. Young, Montpelier, VA (US); Shaileshkumar Ramanlal Desai, Wilmington, NC (US); and Autumn Beauchamp, Wilmington, NC (US)
Assigned to LOBE SCIENCES LTD., Vancouver (CA)
Filed by LOBE SCIENCES LTD., Vancouver (CA)
Filed on Jan. 12, 2024, as Appl. No. 18/411,576.
Application 18/411,576 is a continuation in part of application No. PCT/US2023/027500, filed on Jul. 12, 2023.
Claims priority of provisional application 63/388,414, filed on Jul. 12, 2022.
Prior Publication US 2024/0165080 A1, May 23, 2024
Int. Cl. A61K 31/4045 (2006.01); A61K 9/00 (2006.01); A61P 25/22 (2006.01)
CPC A61K 31/4045 (2013.01) [A61K 9/0053 (2013.01); A61P 25/22 (2018.01)] 20 Claims
 
1. A psilocin formulation comprising psilocin mucate, said formulation exhibiting:
at least 95% bioavailability of psilocin; and/or
at least twice the bioavailability of an equal amount of psilocin generated by metabolism of psilocybin; and/or
no food effect upon oral administration; and/or
at least a 2-fold decrease in time to maximum concentration (Tmax) as compared to an equivalent formulation of psilocybin.